TransCode Therapeutics, Inc.
RNAZHealthcare|Biotechnology|US
$1.49
-0.02 (-1.32%)
DCF Value
$26.00
Cash / Share
$8.95
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05868226 PRE-ISPY Phase I/II Oncology Platform Program | HER2-positive Breast Cancer, Metastatic Cancer | P1P2 | Recruiting | 280 | Open-label | ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 |
| NCT06260774 Study of TTX-MC138 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Active | 16 | Open-label | TTX-MC138 |
| NCT05908773 A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Early P1 | Completed | 1 | Open-label | TTX-MC138-NODAGA-Cu64 |